Fabentech Revenue

Pharmaceutical Manufacturing • Lyon, Auvergne-Rhône-Alpes, France • 51-100 Employees

Fabentech revenue & valuation

Annual revenue	$8,966,028
Revenue per employee	$138,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$28,700,000
Total funding	$39,600,000

Key Contact at Fabentech

Bertrand Lepine

Founder - Board Member

Company overview

Headquarters	24, rue Jean Baldassini, Bâtiment B, Lyon, 69007, FR
Phone number	+33437706767
Websites	fabentech.com fabentech.fr
NAICS	3254
SIC	283
Keywords	Emergency, Pandemic, Immunotherapy, Antibody, Antibodies, Infectious Diseases, Ebola, Infectious Disease, Emerging, Bioterrorism, Drug Abuse, Nosocomial, Poison, Antidote, Antitoxin, Bioweapon, Epidemic, Narcotic Dependence, Polyclonal
Founded	2009
Employees	51-100
Socials

Fabentech Email Formats

Fabentech uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@fabentech.com), used 53.7% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@fabentech.com	53.7%
{first initial}.{last name}	j.doe@fabentech.com	46.3%

About Fabentech

Fabentech is a privately owned biopharmaceutical SME based in Lyon (France) and created in 2009, which develops immunotherapies to address situations of emergency. In an environment where the globalization of trade accelerates the spread of epidemics and where the geopolitical context increases the risk of bioterrorist attacks, nations should be prepared to address various situations of public health & medical emergency. However, there is generally no real therapeutic option to fight acute symptoms arising from these neglected indications. Based on its horse F(ab’)2 platform, a fully-derisked technology in-licensed from Sanofi Pasteur, Fab’entech aims to provide therapeutic solutions in the fields of biodefense, drug intoxication and infectious disease. After having developed Fabenflu®, a product indicated for the treatment of avian influenza (H5N1) in human, Fab’entech is currently focusing on 3 products: a biodefense antidote developed in collaboration with the French army, a treatment for drug intoxication developed in a confidential indication, and an Ebola therapy developed with the support of the European Commission after having been identified by the WHO as the unique therapeutic solution in Europe in 2014.

Employees by Management Level

Total employees: 51-100

Seniority

Employees

Manager

Entry

Head

Employees by Department

Fabentech has 45 employees across 8 departments.

Departments

Number of employees

Funding Data

Explore Fabentech's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount
2020-03-03	6	$9,400,000
2024-03-01	9	$8,300,000
2024-11-07	12	$21,900,000

Funding Insights

$39,600,000

Total funding amount

$21,900,000

Most recent funding amount

Number of funding rounds

Fabentech Tech Stack

Discover the technologies and tools that power Fabentech's digital infrastructure, from frameworks to analytics platforms.

Apache HTTP Server

Web servers

PHP

Programming languages

Open Graph

Miscellaneous

WordPress

Blogs

IONOS

Hosting

WPML

Translation

MySQL

Databases

Yoast SEO

SEO

Frequently asked questions

Fabentech is located in Lyon, Auvergne-Rhône-Alpes, FR.

You can reach Fabentech at +33437706767.

Fabentech generates an estimated annual revenue of $8,966,028. This revenue figure reflects the company's market position and business performance in its industry.

Fabentech has an estimated valuation of $28,700,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Fabentech was founded in 2009, making it 17 years old. The company has established itself as a significant player in its industry over this time.

Fabentech has approximately 51-100 employees. The company continues to grow its workforce to support its business operations and expansion.

Fabentech has raised a total of $39,600,000 across 3 funding rounds. This investment has helped the company grow and expand its operations.

Key Contact at Fabentech

Bertrand Lepine

Founder - Board Member

4.8

40,000 users